Literature DB >> 26592252

EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway.

Hao Zhang1,2, Huizi Gu3, Limei Li4, Yuan Ren1, Lijun Zhang5.   

Abstract

In this study, we examined the mechanisms associated with EZH2 mediation of apoptosis and chemoresistance to arsenic trioxide (ATO) in acute myeloid leukemia (AML) cell lines through the Wnt/β-catenin signaling pathway. The induction of spontaneous apoptosis observed in multiple EZH2-silenced leukemic cell lines was assessed by flow cytometry, and levels of Wnt/β-catenin-related expression were determined by western blot analysis. In comparison with AML control cells, EZH2-knockdown cells exhibited increased apoptosis and significant downregulation of β-catenin expression, as well as decreases in GSK-3β phosphorylation and β-catenin activation (p < 0.05 for all measurements). Additionally, EZH2 knockdown sensitized AML cells to induced cell death following administration of chemotherapeutic ATO. Our results suggested that EZH2 in leukemic cell lines might inhibit ATO-induced apoptosis and that EZH2 may be a potential therapeutic target in AML patients undergoing ATO treatment. Our findings provide new insights into the role of ATO and EZH2 in regulating AML progression.

Entities:  

Keywords:  ATO; Acute myeloid leukemia; EZH2; Wnt/β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26592252     DOI: 10.1007/s13277-015-4463-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.

Authors:  Masashi Takawa; Ken Masuda; Masaki Kunizaki; Yataro Daigo; Katsunori Takagi; Yukiko Iwai; Hyun-Soo Cho; Gouji Toyokawa; Yuka Yamane; Kazuhiro Maejima; Helen I Field; Takaaki Kobayashi; Takayuki Akasu; Masanori Sugiyama; Eijyu Tsuchiya; Yutaka Atomi; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Cancer Sci       Date:  2011-05-26       Impact factor: 6.716

Review 2.  Expanding the use of arsenic trioxide: leukemias and beyond.

Authors:  Zhu Chen; Guo-Qiang Chen; Zhi-Xiang Shen; Guan-Lin Sun; Jian-Hua Tong; Zhen-Yi Wang; Sai-Juan Chen
Journal:  Semin Hematol       Date:  2002-04       Impact factor: 3.851

Review 3.  Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.

Authors:  A J Murgo
Journal:  Oncologist       Date:  2001

4.  Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

Authors:  Nina Wagener; Stephan Macher-Goeppinger; Maria Pritsch; Johannes Hüsing; Karin Hoppe-Seyler; Peter Schirmacher; Jesco Pfitzenmaier; Axel Haferkamp; Felix Hoppe-Seyler; Markus Hohenfellner
Journal:  BMC Cancer       Date:  2010-10-04       Impact factor: 4.430

5.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

6.  Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects.

Authors:  Germano Baj; Alberto Arnulfo; Silvia Deaglio; Roberto Mallone; Alessandro Vigone; Maria Grazia De Cesaris; Nicola Surico; Fabio Malavasi; Enza Ferrero
Journal:  Breast Cancer Res Treat       Date:  2002-05       Impact factor: 4.872

Review 7.  Arsenical-based cancer drugs.

Authors:  Pierre J Dilda; Philip J Hogg
Journal:  Cancer Treat Rev       Date:  2007-07-10       Impact factor: 12.111

8.  Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.

Authors:  Sooryanarayana Varambally; Qi Cao; Ram-Shankar Mani; Sunita Shankar; Xiaosong Wang; Bushra Ateeq; Bharathi Laxman; Xuhong Cao; Xiaojun Jing; Kalpana Ramnarayanan; J Chad Brenner; Jindan Yu; Jung H Kim; Bo Han; Patrick Tan; Chandan Kumar-Sinha; Robert J Lonigro; Nallasivam Palanisamy; Christopher A Maher; Arul M Chinnaiyan
Journal:  Science       Date:  2008-11-13       Impact factor: 47.728

9.  Analysis of the coding genome of diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Vladimir Trifonov; Giulia Fabbri; Jing Ma; Davide Rossi; Annalisa Chiarenza; Victoria A Wells; Adina Grunn; Monica Messina; Oliver Elliot; Joseph Chan; Govind Bhagat; Amy Chadburn; Gianluca Gaidano; Charles G Mullighan; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

10.  Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Authors:  Ryan D Morin; Nathalie A Johnson; Tesa M Severson; Andrew J Mungall; Jianghong An; Rodrigo Goya; Jessica E Paul; Merrill Boyle; Bruce W Woolcock; Florian Kuchenbauer; Damian Yap; R Keith Humphries; Obi L Griffith; Sohrab Shah; Henry Zhu; Michelle Kimbara; Pavel Shashkin; Jean F Charlot; Marianna Tcherpakov; Richard Corbett; Angela Tam; Richard Varhol; Duane Smailus; Michelle Moksa; Yongjun Zhao; Allen Delaney; Hong Qian; Inanc Birol; Jacqueline Schein; Richard Moore; Robert Holt; Doug E Horsman; Joseph M Connors; Steven Jones; Samuel Aparicio; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330

View more
  2 in total

1.  Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells.

Authors:  Ying Shi; Tong Cao; Hua Huang; Chaoqun Lian; Ying Yang; Zhiwei Wang; Jia Ma; Jun Xia
Journal:  Cell Cycle       Date:  2017-11-20       Impact factor: 4.534

2.  Downregulation of Enhancer of Zeste Homolog 2 (EZH2) is essential for the Induction of Autophagy and Apoptosis in Colorectal Cancer Cells.

Authors:  Yizhou Yao; Hao Hu; Yong Yang; Guoqiang Zhou; Zengfu Shang; Xiaodong Yang; Kang Sun; Shenghua Zhan; Zhengyuan Yu; Peiyao Li; Guofeng Pan; Liang Sun; Xinguo Zhu; Songbing He
Journal:  Genes (Basel)       Date:  2016-10-03       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.